Search
Descriptor English: Certolizumab Pegol
Descriptor Spanish: Certolizumab Pegol
Descriptor certolizumab pegol
Scope note: Fragmento Fab' de polietileno glicosilado del anticuerpo FACTOR DE NECROSIS TUMORAL que se une específicamente a TNF-ALFA y la neutraliza en una modalidad dosis-dependiente. También inhibe la producción de lipopolisacáridos inducidos por TNF-ALFA e IL-1 BETA y se utiliza para tratar la ARTRITIS REUMATOIDE y ARTRITIS PSORIÁSICA.
Descriptor Portuguese: Certolizumab Pegol
Descriptor French: Certolizumab pégol
Entry term(s): CDP 870
CDP870
Cimzia
Tree number(s): D05.750.741.125
D12.644.541.500.650.250
D12.776.124.486.485.114.224.060.500
D12.776.124.486.485.680.650.250
D12.776.124.790.651.114.224.060.500
D12.776.124.790.651.680.650.250
D12.776.377.715.548.114.224.200.500
D12.776.377.715.548.680.650.250
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000068582
Scope note: A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Immunosuppressive Agents
Antirheumatic Agents
Registry Number: UMD07X179E
Public MeSH Note: 2016; CERTILIZUMAB PEGOL was indexed under IMMUNOGLOBULIN FAB FRAGMENTS 2003-2015, POLYETHYLENE GLYCOLS 2003-2015, and under ANTIBODIES, MONOCLONAL, HUMANIZED 2003-2015
History Note: 2016 (2003)
Related: Tumor Necrosis Factor-alpha MeSH
DeCS ID: 55953
Unique ID: D000068582
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2016/01/01
Date of Entry: 2015/07/10
Revision Date: 2017/04/10
Certolizumab Pegol - Preferred
Concept UI M0507051
Scope note A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
Preferred term Certolizumab Pegol
Cimzia - Narrower
Concept UI M0522752
Preferred term Cimzia
CDP870 - Narrower
Concept UI M0442269
Preferred term CDP870
Entry term(s) CDP 870



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey